Rethinking ADC Design: Lessons from NBE-002 and the Potency of PNU-159682

Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted cancer therapeutics, combining the specificity of monoclonal antibodies with the cytotoxicity of potent payloads. The development of NBE-002*, an ROR1-targeted ADC using the highly potent anthracycline derivative PNU-159682, provides valuable insights into the opportunities and challenges of ADC chemical design. By examining the story of NBE-002, we can better understand how payload potency, linker chemistry, and conjugation strategy determine both preclinical promise and clinical limitations.[1][2]

The Promise of PNU-159682
PNU-159682 is a highly potent secondary metabolite of nemorubicin, belonging to the anthracycline class of natural products. A morpholinyl analogue of doxorubicin, nemorubicin is significantly more potent than doxorubicin; it also acts on multidrug-resistant (MDR) cells and is not cardiotoxic at therapeutic doses. [3][4] Identified as the most active product of CYP3A4-mediated metabolism of nemorubicin, PNU-159682 acts as a DNA topoisomerase II inhibitor, inducing DNA damage and cell cycle arrest with far greater potency than classical anthracyclines like doxorubicin.** Its cytotoxic activity is observed in the picomolar range, making it highly attractive for inclusion in ADCs, particularly for tumors with low target-antigen density.[5][6]

Due to its unique structure—a rigid, polycyclic anthracycline—PNU-159682 demonstrates efficient DNA intercalation and cytotoxicity. It has been successfully conjugated to antibodies targeting both internalizing and non-internalizing tumor antigens, showing potent anti-tumor effects in preclinical models, including ADC-resistant cancer lines. For example, PNU-159682 derivatives have been coupled to anti-CD22 and anti-tenascin-C antibodies, yielding ADCs with robust in vivo activity.[6][7]

NBE-002: Targeting ROR1 with a Potent Payload
ROR1 (Receptor tyrosine kinase-like orphan receptor 1) is an oncofetal protein often overexpressed in multiple malignancies, driving tumor progression, metastasis, and stemness. High ROR1 expression is generally associated with aggressive and resistant disease, including in mantle cell lymphoma, B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), high-grade serous ovarian cancer (HGSOC), pancreatic cancer, and colorectal cancer, and other tumor types—but largely absent in normal adult tissues. This restricted expression profile makes ROR1 an appealing ADC target for delivering cytotoxic payloads selectively to cancer cells. [8][9][10]

Advertisement #3 

 

NBE-002 (huXBR1-402-G5-PNU)*** is a first-in-class immune-stimulatory ADC (iADC) that links a humanized anti-ROR1 antibody (huXBR1-402) to a derivative of PNU-159682 using SMAC-technology™ (Sortase-Mediated Antibody Conjugation), a proprietary, site-specific enzymatic conjugation platform developed by NBE-Therapeutics to create highly homogeneous, stable ADCs. The technology uses Staphylococcus aureus sortase A to covalently attach payloads to engineered C-termini of antibodies, enhancing ADC stability, potency, and therapeutic index. The ADC demonstrated:

• Potent cytotoxicity in vitro against ROR1+ cell lines, including B-ALL, mantle cell lymphoma, and HGSOC, with apoptosis induction and G2/M cell cycle arrest.
• In vivo efficacy in mouse xenograft and leukemia models, suppressing tumor growth and prolonging survival with minimal toxicity.
• Synergy with BCL2 inhibition: Combining NBE-002 with venetoclax (Venclexta®; AbbVie and Genentech), a BCL2 inhibitor, enhanced cytotoxicity in BCL2-dependent leukemias, highlighting the value of combination strategies.
• Synergy with chemotherapy: In HGSOC models, NBE-002 showed additive or synergistic activity with carboplatin and olaparib (a PARP inhibitor), overcoming chemotherapy resistance in selected cases.

Challenges Revealed: The Limits of Potency and Hydrophobicity
Studies with NBE-002 in PDX models of several carcinoma and sarcoma subtypes with low, intermediate, and high ROR1 expression demonstrated a notable anti-tumor effect in triple-negative breast cancer (TNBC), at doses as low as 0.033 mg/kg, suggesting a best-in-class therapeutic index, especially in light of the high tolerability in preclinical toxicology models. But despite its strong (pre)clinical potential, the Phase 1/2 clinical trial (NCT04441099) of NBE-002 for advanced solid tumors was terminated in September 2023. There have been no recent reports of active development. This outcome reflects a broader challenge for highly potent, hydrophobic, DNA-binding payloads like PNU-159682:

• Aggregation and Instability: The hydrophobicity of PNU-159682 can promote ADC aggregation, compromising pharmacokinetics and increasing the risk of off-target toxicity.
• Narrow Therapeutic Window: While the payload’s high potency can improve tumor cell killing, it also increases the risk of harming normal, healthy tissues if the ADC is unstable or released prematurely.
• Off-Target Effects: Even with target specificity, highly potent payloads can generate toxicities if the conjugate is not sufficiently stable or if there is low-level antigen expression on normal cells.

Toward Smarter ADC Chemical Design
The NBE-002 experience underscores several strategies for overcoming these challenges:

Reduce Hydrophobicity

• Incorporate polar or ionizable groups in the payload.
• Use hydrophilic linkers (e.g., PEGylation, polysarcosine) or masking strategies to improve solubility and minimize aggregation.

Optimize Conjugation and Linker Chemistry

• Employ site-specific conjugation to achieve homogeneity and optimal drug-to-antibody ratio (DAR).
• Design linkers that remain stable in circulation but are efficiently cleaved within the tumor microenvironment (e.g., enzyme- or pH-sensitive linkers).

Expand the Therapeutic Index

• Consider payload attenuation (tuning potency rather than maximizing it for safety).
• Develop dual-payload or synergistic ADCs that combine mechanisms.
• Explore combination regimens, such as ADCs plus BCL2 inhibitors, to improve efficacy in resistant cancers.

Broader Implications and Future Directions
NBE-002 and related PNU-159682-based ADCs highlight the evolving landscape of ADC payload chemistry. While extremely potent cytotoxins can enhance efficacy, their use demands careful consideration of stability, solubility, and therapeutic index. The clinical development of ADCs also depends on understanding the biology of the target antigen, tumor proliferation dynamics, and resistance mechanisms. Notably, ROR1 remains a promising target across both solid and hematologic malignancies, as demonstrated by the activity of NBE-002 and other anti-ROR1 ADCs.

The experience with NBE-002 and PNU-159682 illustrates that the future of ADCs will depend on smarter chemical design—balancing potency, stability, and selectivity. Advances in linker technology, site-specific conjugation, and rational payload selection will be essential for realizing the full clinical potential of ADCs. As the field matures, lessons from both successes and setbacks will continue to inform the next generation of targeted cancer therapeutics.

__

Note:* NBE-002 was originally developed by NBE Therapeutics, which was acquired by Boehringer Ingelheim in December 2020 for approximately $1.5 billion, making it part of their portfolio. In early 2025, NBE Therapeutics, a wholly owned subsidiary of Boehringer Ingelheim, opened its new ADC R&D facility in Basel, Switzerland.

** PNU-159682 is an anthracycline derivative that, in addition to DNA intercalation, inhibits topoisomerase I, which is essential for DNA replication.

*** The huXBR1-402 antibody is a humanized version of the human monoclonal ROR1 monoclonal antibody XBR1-402 generated through phage display libraries and validated with next-generation sequencing. [R3]

Clinical trials
NBE-002 in Patients With Advanced Solid Tumors – ClinicalTrials.gov ID NCT04441099

Highlights of Prescription Information
Venetoclax (Venclexta®; AbbVie and Genentech)[Prescribing Information]

Reference
[1] Liu D, Vandenberg CJ, Sini P, Waldmeier L, Baumgartinger R, Pisarsky L, Petroczi G, Ratnayake G, Scott CL, Ford CE. The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models. Ther Adv Med Oncol. 2025 Apr 21;17:17588359251332471. doi: 10.1177/17588359251332471. PMID: 40297621; PMCID: PMC12034953.
[2] Tolcher AW, Meric-Bernstam F, McKean M, Beerli RR, Waldmeier L, Gebleux R, Hellmann I, Chrom P, Grawunder U. NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial. J Clin Oncol 39, TPS1108-TPS1108(2021). DOI:10.1200/JCO.2021.39.15_suppl.TPS1108
[3] Mariani M, Capolongo L, Suarato A, Bargiotti A, Mongelli N, Grandi M, Beck WT. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs. 1994;12(2):93-7. doi: 10.1007/BF00874437. PMID: 7860237.
[4] Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, Del Tacca M. 3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer. 1993;29A(11):1560-5. doi: 10.1016/0959-8049(93)90295-q. PMID: 8217363.
[5] Holte D, Lyssikatos JP, Valdiosera AM, Swinney Z, Sisodiya V, Sandoval J, Lee C, Aujay MA, Tchelepi RB, Hamdy OM, Gu C, Lin B, Sarvaiya H, Pysz MA, Laysang A, Williams S, Jun Lee D, Holda MK, Purcell JW, Gavrilyuk J. Evaluation of PNU-159682 antibody drug conjugates (ADCs). Bioorg Med Chem Lett. 2020 Dec 15;30(24):127640. doi: 10.1016/j.bmcl.2020.127640. Epub 2020 Oct 28. PMID: 33127540.
[6] Mazzini S, Scaglioni L, Mondelli R, Caruso M, Sirtori FR. The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Bioorg Med Chem. 2012 Dec 15;20(24):6979-88. doi: 10.1016/j.bmc.2012.10.033. Epub 2012 Nov 3. PMID: 23154079.
[7] Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer. 1994 Jul;70(1):79-84. doi: 10.1038/bjc.1994.253. PMID: 8018545; PMCID: PMC2033319.
[8] Wu ZL, Wang Y, Jia XY, Wang YG, Wang H. Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers. World J Clin Oncol. 2024 May 24;15(5):603-613. doi: 10.5306/wjco.v15.i5.603. PMID: 38835843; PMCID: PMC11145958.
[9] Jung MS, Choi WY, Zhang W, Barrera FN, Perkins RS. The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling. Int J Mol Sci. 2025 Aug 13;26(16):7828. doi: 10.3390/ijms26167828. PMID: 40869147; PMCID: PMC12386924.
[10] Hu EY, Do P, Goswami S, Nunes J, Chiang CL, Elgamal S, Ventura AM, Cheney C, Zapolnik K, Williams E, Mani R, Frissora F, Mo X, Waldmeier L, Beerli RR, Peng H, Rader C, Long M, Grawunder U, Byrd JC, Muthusamy N. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Adv. 2021 Aug 24;5(16):3152-3162. doi: 10.1182/bloodadvances.2020003276. PMID: 34424320; PMCID: PMC8405197.

Featured image: NBE Therapeutics/Technologiepark Basel. Image Courtesy © 2016 – 2026 Technologiepark Basel AG. Used with permission

DOI: 10.14229/jadc.2026.10.04.001